These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38962436)

  • 1. Dietary supplementation with a wild green oat extract (
    Friling M; García-Muñoz AM; Lavie A; Pérez-Piñero S; Victoria-Montesinos D; López-Román FJ; García-Guillén AI; Muñoz-Carrillo JC; Cánovas F; Ivanir E; Jalanka J
    Front Nutr; 2024; 11():1405156. PubMed ID: 38962436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute effects of a wild green-oat (Avena sativa) extract on cognitive function in middle-aged adults: A double-blind, placebo-controlled, within-subjects trial.
    Kennedy DO; Jackson PA; Forster J; Khan J; Grothe T; Perrinjaquet-Moccetti T; Haskell-Ramsay CF
    Nutr Neurosci; 2017 Feb; 20(2):135-151. PubMed ID: 26618715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute and Chronic Effects of Green Oat (
    Kennedy DO; Bonnländer B; Lang SC; Pischel I; Forster J; Khan J; Jackson PA; Wightman EL
    Nutrients; 2020 May; 12(6):. PubMed ID: 32485993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic effects of a wild green oat extract supplementation on cognitive performance in older adults: a randomised, double-blind, placebo-controlled, crossover trial.
    Wong RH; Howe PR; Bryan J; Coates AM; Buckley JD; Berry NM
    Nutrients; 2012 May; 4(5):331-42. PubMed ID: 22690320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of nicotine lozenges on affective smoking withdrawal symptoms: secondary analysis of a randomized, double-blind, placebo-controlled clinical trial.
    Shiffman S
    Clin Ther; 2008 Aug; 30(8):1461-75. PubMed ID: 18803988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Combination Treatment With Varenicline and Nicotine Patch on Smoking Cessation Among Smokers Who Drink Heavily: A Randomized Clinical Trial.
    King A; Vena A; de Wit H; Grant JE; Cao D
    JAMA Netw Open; 2022 Mar; 5(3):e220951. PubMed ID: 35244704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.
    Tsai ST; Cho HJ; Cheng HS; Kim CH; Hsueh KC; Billing CB; Williams KE
    Clin Ther; 2007 Jun; 29(6):1027-39. PubMed ID: 17692719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smoking cessation for improving mental health.
    Taylor GM; Lindson N; Farley A; Leinberger-Jabari A; Sawyer K; Te Water Naudé R; Theodoulou A; King N; Burke C; Aveyard P
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013522. PubMed ID: 33687070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial.
    Lüthi H; Lengsfeld S; Burkard T; Meienberg A; Jeanloz N; Vukajlovic T; Bologna K; Steinmetz M; Bathelt C; Sailer CO; Laager M; Vogt DR; Hemkens LG; Speich B; Urwyler SA; Kühne J; Baur F; Lutz LN; Erlanger TE; Christ-Crain M; Winzeler B
    EClinicalMedicine; 2024 Feb; 68():102429. PubMed ID: 38371479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
    Gonzales D; Rennard SI; Nides M; Oncken C; Azoulay S; Billing CB; Watsky EJ; Gong J; Williams KE; Reeves KR;
    JAMA; 2006 Jul; 296(1):47-55. PubMed ID: 16820546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.
    Nakamura M; Oshima A; Fujimoto Y; Maruyama N; Ishibashi T; Reeves KR
    Clin Ther; 2007 Jun; 29(6):1040-56. PubMed ID: 17692720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior.
    Jones JD; Babalonis S; Marcus R; Vince B; Kelsh D; Lofwall MR; Fraser H; Paterson B; Martinez S; Martinez DM; Nunes EV; Walsh SL; Comer SD
    Addict Biol; 2020 Jul; 25(4):e12799. PubMed ID: 31240842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions to reduce harm from continued tobacco use.
    Lindson-Hawley N; Hartmann-Boyce J; Fanshawe TR; Begh R; Farley A; Lancaster T
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005231. PubMed ID: 27734465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Trial of Nicotine Inhaler for Pregnant Smokers.
    Oncken C; Dornelas EA; Kuo CL; Sankey HZ; Kranzler HR; Mead EL; Thurlow MSD
    Am J Obstet Gynecol MFM; 2019 Mar; 1(1):10-18. PubMed ID: 31380506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ending Tobacco Use Through Interactive Tailored Messaging for Cambodian People With HIV (Project EndIT): Protocol for a Randomized Controlled Trial.
    Bui TC; Hoogland CE; Chhea C; Sopheab H; Ouk V; Samreth S; Hor B; Vidrine JI; Businelle MS; Shih YCT; Sutton SK; Jones SR; Shorey Fennell B; Cottrell-Daniels C; Frank-Pearce SG; Ngor C; Kulkarni S; Vidrine DJ
    JMIR Res Protoc; 2023 Jun; 12():e48923. PubMed ID: 37384390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytisinicline for Smoking Cessation: A Randomized Clinical Trial.
    Rigotti NA; Benowitz NL; Prochaska J; Leischow S; Nides M; Blumenstein B; Clarke A; Cain D; Jacobs C
    JAMA; 2023 Jul; 330(2):152-160. PubMed ID: 37432430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
    Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
    JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The possible "calming effect" of subchronic supplementation of a standardised phospholipid carrier-based
    Bano A; Hepsomali P; Rabbani F; Farooq U; Kanwal A; Saleem A; Bugti AA; Khan AA; Khalid Z; Bugti M; Mureed S; Khan S; Ujjan ID; Şahin S; Kara M; Khan A
    Front Pharmacol; 2023; 14():1250560. PubMed ID: 37927585
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.